Finally, new strategies bring some good prospects for our inflammatory bowel disease patients (notice n° 1921141)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01941cam a2200157 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260329022605.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Roblin, Xavier |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Finally, new strategies bring some good prospects for our inflammatory bowel disease patients |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 33 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Two recurring questions arise for gastroenterologists treating patients with inflammatory bowel disease (IBD): Does treatment of IBD with immunosuppressants or biotherapies have an impact on male fertility and on subsequent pregnancy outcomes for couples? In pregnant women, when is the best time to stop anti-TNF treatment during pregnancy, and when should the newborn be administered a live-attenuated vaccine? A review of the literature and a meta-analysis collated studies describing the consequences of IBD treatment with biotherapy or immunosuppressants on spermatogenesis and the development of a possible pregnancy in couples. Sperm analysis, including sperm count, morphology, and motility, did not differ with or without treatment. Rates of adverse pregnancy events (miscarriage, prematurity, and congenital malformation) were not significantly different according to whether or not the male parents had received treatment for IBD. Recommendations concerning the use of biotherapies have recently been drawn up by the European group ECCO (European Crohn’s and Colitis Organization). A physiologically-based pharmacokinetic modelling study of biotherapies in both pregnant women and exposed children sought to predict the ideal timing for the final biotherapy injection, taking into account the mother’s dose and the intervals between injections or infusions. |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 1 | 2022-01-01 | p. 9-11 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-1-page-9?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-hepato-gastro-oncologie-digestive-2022-1-page-9?lang=en&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux